References
- Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179-203. DOI: 10.1007/s10555-020-09925-3
- Fuchs CS, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022;25(1):197-206. DOI: 10.1007/s10120-021-01227-z
- Zhu M, Zhang P, Yu S, Tang C, Wang Y, Shen Z, et al. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer. J Exp Clin Cancer Res. 2022;41(1):14. DOI: 10.1186/s13046-021-02224-x
- Wang S, Hu M, Qian Y, Jiang Z, Shen L, Fu L, et al. CHI3L1 in the pathophysiology and diagnosis of liver diseases. Biomed Pharmacother. 2020;131:110680. DOI: 10.1016/j. biopha.2020.110680
- Lananna BV, McKee CA, King MW, Del-Aguila JL, Dimitry JM, Farias FHG, et al. Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis. Sci Transl Med. 2020;12(574):eaax3519. DOI: 10.1126/scitranslmed.aax3519
- Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18(1):135. DOI: 10.1186/s12943-019-1063-6
- Ni H, Chen Y, Xia W, Wang C, Hu C, Sun L, et al. SATB2 Defect Promotes Colitis and Colitis-associated Colorectal Cancer by Impairing Cl-/HCO3- Exchange and Homeostasis of Gut Microbiota. J Crohns Colitis. 2021;15(12):2088-102. DOI: 10.1093/ecco-jcc/jjab094
- Digestive Endoscopy Branch of Chinese Medical Association. Consensus opinion on early gastric cancer screening and endoscopic diagnosis and treatment in China (Changsha, 2014). Chinese Journal of Gastroenterology. 2014;34(7):433-48.
- Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624
- Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park SM, et al. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Gastric Cancer. 2019;22(6):1153-63. DOI: 10.1007/s10120-019-00971-7
- Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, et al. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer. 2022;128(5):995-1003. DOI: 10.1002/cncr.34019
- Cheng X, Yang F, Wang Y, Nie W, Mahendra Upadhyay A, Zhang M, et al. Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis. Can J Gastroenterol Hepatol. 2022;2022:6015877. DOI: 10.1155/2022/6015877
- Johansen JS, Williamson MK, Rice JS, Price PA. Identification of peokrins secreted by human osteoblastic cells in culture. J Bone Miner Res. 1992;7(5):501-12. DOI: 10.1002/jbmr.5650070506
- Kawada M, Seno H, Kanda K, Nakanishi Y, Akitake R, Komekado H, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 2012;31(26):3111-23. DOI: 10.1038/onc.2011.498
- Libreros S, Garcia-Areas R, Shibata Y, Carrio R, Torroella-Kouri M, Iragavarapu-Charyulu V. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment:decreased tumor metastasis in a breast cancer model. Int J Cancer. 2012;131(2):377-86. DOI: 10.1002/ijc.26379
- Min L, Zhu S, Wei R, Zhao Y, Liu S, Li P, et al. Integrating SWATHMS Proteomics and Transcriptome Analysis Identifies CHI3L1 as a Plasma Biomarker for Early Gastric Cancer. Mol Ther Oncolytics. 2020;17:257-66. DOI: 10.1016/j.omto.2020.03.020
- Geng B, Pan J, Zhao T, Ji J, Zhang C, Che Y, et al. Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-tomesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer. J Exp Clin Cancer Res. 2018;37(1):208. DOI: 10.1186/s13046-018-0876-2
- Chen QY, Des Marais T, Costa M. Deregulation of SATB2 in carcinogenesis with emphasis on miRNA-mediated control. Carcinogenesis. 2019;40(3):393-402. DOI: 10.1093/carcin/bgz020
- Wu L, Chen J, Qin Y, Mo X, Huang M, Ru H, et al. SATB2 suppresses gastric cancer cell proliferation and migration. Tumour Biol. 2016;37(4):4597-602. DOI: 10.1007/s13277-015-4282-5
- Mezheyeuski A, Ponten F, Edqvist PH, Sundström M, Thunberg U, Qvortrup C, et al. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncol. 2020;59(3):284-90. DOI: 10.1080/0284186X.2019.1691258
- Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlén M, Ericson Lindquist K, et al. A coliort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 2012;106(5):931-8. DOI: 10.1038/bjc.2012.34